SUBSCRIBE
Drivetime Radio

Interviews for Australia’s Specialists…

This exclusive audio series brings together specialists to delve into the most up-to-date clinical data and insights.

Tune in to our medical broadcasters as they moderate captivating and enlightening discussions with renowned experts and influential thought leaders. With our easy search feature, you can filter interviews based on your specific area of interest, ensuring that you receive relevant. and targeted discussions.

Listen now, exclusively for healthcare professionals, available online and as a private podcast.

 

Search Interviews

By area of interest:

Specialty Interviews

Epi.3Addressing the treatment gaps with generalised tonic-clonic seizures (20-mins)
00:00
Preview
10 seconds
Show more information

Epilepsy, Part 3 UCB series: There is universal agreement that primary generalised tonic-clonic seizures (PGTCS) are the most severe form of epileptic seizure. The treatment of PGTCS has been the subject of relatively few robust clinical studies, leading to significant unmet clinical needs in this patient population. Not only are there few treatment options available, but a significant proportion of patients who are treated with currently available drugs have insufficient seizure control or unacceptable drug tolerability. In this interview we discuss the importance of optimising the early treatment of PGTCS, including treatments with demonstrated effectiveness in this group. 20-minute listen

Hosted by

Professor Mark Cook

Interviewees

  • A/Prof. Lata Vadlamundi, Neurologist, The Royal Brisbane and Women’s Hospital, Brisbane.A/Prof. Lata Vadlamundi, Neurologist, The Royal Brisbane and Women’s Hospital, Brisbane.
Gas.4The forgotten part of ulcerative colitis (26 mins)
00:00
Preview
10 seconds
Show more information

The treatment paradigm in ulcerative colitis (UC) is rapidly evolving beyond symptom control with the aim of achieving mucosal healing and steroid-free remission, associated with reduced rates of UC-related hospital admissions, avoiding the need for a colectomy, and improving quality of life.

It’s important that we make the most of the treatments we have, and not give up on a treatment if there’s a chance to make it work. In this interview we discuss the optimisation of 5-ASA medications in the management of patients with mild to moderate UC.

Hosted by

Associate Professor Mayur Garg

Interviewees

  • Prof. Peter Irving, Gastroenterologist, Guy's and St Thomas' Hospital, London, UK.Prof. Peter Irving, Gastroenterologist, Guy's and St Thomas' Hospital, London, UK.
Endo.1New developments in diabetes (20mins)
00:00
Preview
10 seconds
Show more information

Endocrinology: Prof. MacIssac and A/Prof. Rasalam were both lead authors in a recent review titled, ‘Challenging clinical perspectives in type 2 diabetes with tirzepatide, a first-in-class twincretin’ published in Diabetes Therapy. In this interview Prof. MacIssac and A/Prof. Rasalam discuss key highlights of this review, as well as how these developments may affect the treatment algorithm of type 2 diabetes in Australia.

Hosted by

Professor Richard Maclsaac

Interviewees

  • Associate Professor Roy Rasalam from the University of MelbourneAssociate Professor Roy Rasalam from the University of Melbourne
Hae.1A new triplet combination for the treatment of relapsed and refractory multiple myeloma (27mins)
00:00
Preview
10 seconds
Show more information

For haematologists, myeloma remains one of the most challenging diseases we deal with, there is no ‘one-size-fits-all’ approach to the management of multiple myeloma, and this is especially true for relapsed or refractory disease. With the right choice of agents we can control the disease for many years , but how we sequence those agents and how we use them in combination really is something we’re still working out, and we’re often dealing with limitations from the Pharmaceutical Benefits Scheme. In this interview we talk through these challenges, to help navigate this journey in clinical practice.

Hosted by

Professor Christopher Ward

Interviewees

  • Prof. Hang Quach, Director of Clinical Haematology & Clinical Haematology Research, St Vincent’s Hospital, Melbourne,Prof. Hang Quach, Director of Clinical Haematology & Clinical Haematology Research, St Vincent’s Hospital, Melbourne,
  • Dr Wojt Janowski, Haematologist, Hunter region, NSWDr Wojt Janowski, Haematologist, Hunter region, NSW
Endo.1New developments in induction of labour (24mins)
00:00
Preview
10 seconds
Show more information

Induction of labour is a daily occurrence in obstetric units around Australia, and rates of induction have been rising nationally for the past decade. The Australian Institute of Health and Welfare data shows that in 2020, 46% of first-time mums with an uncomplicated pregnancy had their labour induced. In this interview we explore new developments in the induction of labour.

 

Hosted by

Professor Rod Baber

Interviewees

  • Dr Scott White, Obstetrician & Gynaecologist, Perth, Western AustraliaDr Scott White, Obstetrician & Gynaecologist, Perth, Western Australia
Gas.3Could multidisciplinary team meetings be the future? (22 mins)
00:00
Preview
10 seconds
Show more information

Multidisciplinary team meetings have proven efficacy in cancer management as well as being widely implemented in the management of chronic diseases like inflammatory bowel disease, however not all treating clinicians (particularly those in rural/regional areas, or even many of those in private practices) have access to these high quality and integrated meetings. Given the potential for an MDT-based approach to potentially improve patient quality of care, patient satisfaction and patient outcomes, it only makes sense that such a service can be offered to the wider gastroenterology community.
In this interview we talk to Jake Begun, who along with his team at Queensland IBD have implemented the first dedicated state-wide virtual MDT in Australia.

Hosted by

Associate Professor Mayur Garg

Interviewees

  • A/Prof Jake Begun, Director of Gastroenterology, Mater Hospital Brisbane & A/Prof University of Queensland School of Medicine & Co-Director Queensland IBD A/Prof Jake Begun, Director of Gastroenterology, Mater Hospital Brisbane & A/Prof University of Queensland School of Medicine & Co-Director Queensland IBD 
Gas.2Emerging treatments for moderate to severe inflammatory bowel disease (50mins)
00:00
Preview
10 seconds
Show more information

The past several years have seen an expansion in therapeutic options to care for our patients with IBD, with more agents to come in the near future. Conventional therapies such as thiopurines, methotrexate, aminosalicylates and steroids have been supplemented by the tumour necrosis factor (TNF) inhibitors (ground-breaking when they first arrived), the anti-integrin vedolizumab, the antiIL-12/23 p40 inhibitor ustekinumab and, more recently, the JAK inhibitor tofacitinib over the past few years. Our expectations and treatment goals have subsequently risen substantially, such that our aim for patients is to achieve sustained clinical remission, achieve endoscopic and possibly histologic and transmural healing, prevent complications and achieve as close to a normal quality of life as possible for our patients.

Hosted by

Associate Professor Mayur Garg

Interviewees

  • Prof. Rupert Leong, Consultant Gastroenterologist, Concord Hospital & Prof of Medicine, University of SydneyProf. Rupert Leong, Consultant Gastroenterologist, Concord Hospital & Prof of Medicine, University of Sydney
Psy.10Generalised anxiety disorder…common, and commonly overlooked (20 mins)
00:00
Preview
10 seconds
Show more information

Despite the high prevalence of generalised anxiety disorder in Australia, identification and diagnosis is challenging as patients present with non-specific and varying symptoms. Further complicating diagnosis and treatment is the high prevalence of comorbidities, both physical and psychiatric. The complex interplay between management strategies for multiple conditions has significant impact on treatment selection. In this interview, we discuss these challenges, as well as a newly indicated treatment {agomelatine}.

Hosted by

Professor Malcolm Hopwood

Interviewees

  • Prof Ajeet Singh, Professor of Psychiatry, Geelong, Deakin University, VictoriaProf Ajeet Singh, Professor of Psychiatry, Geelong, Deakin University, Victoria
Hae.1Secondary infections after COVID, with a focus on COVID associated pulmonary aspergillosis (CAPA)
00:00
Preview
10 seconds
Show more information

SARS-CoV-2 infections continue to be a concern in Australia, and while the diagnosis and management of these infections are well understood, we less frequently hear about the diagnosis and management of secondary infections in people with COVID-19.  There are, of course, specific challenges in the diagnosis of secondary infections in COVID-19 patients. However, delayed diagnosis, has very serious consequences, given the high mortality associated with COVID-19 Associated Pulmonary Aspergillosis, or CAPA as it is now known.

Hosted by

Professor Christopher Ward

Interviewees

  • Prof. Paul Verweij, Professor of Clinical Mycology, Radboud University Medical Centre, NetherlandsProf. Paul Verweij, Professor of Clinical Mycology, Radboud University Medical Centre, Netherlands
Epi.2.2Tolerability: A key consideration for antiseizure medication treatment selection (33-minutes)
00:00
Preview
10 seconds
Show more information

Epilepsy: While the need to balance efficacy and safety when weighing up medication choices is well understood, the importance of tolerability can sometimes be underestimated. When it comes to anti-seizure medications, tolerability may carry more weight among people with refractory epilepsy. That’s because the impact of side effects, particularly mood, cognitive and behavioural adverse effects, on general wellbeing and quality of life can be significant. In this interview we are talking about the impact of antiseizure medication side effects on patients, and important tolerability considerations in epilepsy therapy.

Hosted by

Professor Mark Cook

Interviewees

  • Dr Patrick Carney, Deputy Director of Neurology, Box Hill HospitalDr Patrick Carney, Deputy Director of Neurology, Box Hill Hospital

Search Interviews

By area of interest:

Exclusively for Australian healthcare professionals
×

Tap the share icon ios share icon and select 'Add to Home Screen' to add the site to your home screen for quick access!